Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 10/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6539666 | 0.90 | RAB9A (0.58) | RAB9AHPGDNPSR1NPC1TDP1 | |
| SCHEMBL6539004 | 0.84 | RAB9A (0.50) | RAB9AHPGDNPSR1NPC1TDP1 | |
| SCHEMBL6539122 | 0.83 | RAB9A (0.49) | RAB9AHPGDNPSR1NPC1TDP1 | |
| SCHEMBL6539813 | 0.83 | RAB9A (0.49) | RAB9AHPGDNPSR1NPC1TDP1 | |
| SCHEMBL6539811 | 0.83 | RAB9A (0.49) | RAB9AHPGDNPSR1NPC1TDP1 | |
| SCHEMBL6539329 | 0.82 | PPARD (0.41) | ATM | |
| SCHEMBL6538764 | 0.81 | PPARD (0.39) | POLBATMKMT2A | |
| SCHEMBL6539086 | 0.81 | MEN1 (0.45) | HPGDNPSR1POLBHSD17B10KMT2A | |
| SCHEMBL6539490 | 0.79 | PPARD (0.38) | RAB9ANPC1POLB | |
| SCHEMBL6540113 | 0.78 | TP53 (0.39) | RAB9ANPC1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157891-A1 | Inhibitor of cox | PTGS1, PTGS2, PTGES2 | RAB9A 4006/4885HPGD 29/4885NPSR1 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.